[ad_1]
AMERICAN: Johnson & Johnson is among the many struggling to complete a corona vaccine. Photo: BRENDAN MCDERMID / REUTERS / NTB
The American company Johnson & Johnson has put its study of vaccines on hold after they discovered the disease in one of the participants.
This is confirmed by Johnson & Johnson in a press release Tuesday evening. It was statnews.com that first reported that testing of the vaccine had been suspended.
– We temporarily stopped further testing of all our clinical trials with the Covid-19 vaccine, including the phase 3 vaccine, due to unexplained illness in one of the participants. According to our guidelines, the disease is examined and evaluated by the independent Data Stability Monitoring Board, the company writes.
Follow the vaccine race here
Janssen Pharmaceutical Companies, which is owned by Johnson & Johnson, is collaborating with the American Beth Israel Deaconess Medical Center on the development of the corona vaccine. The EU is among those who have signed an agreement to buy this vaccine for its member countries, and Norway, if it is completed.
The company began phase three of the trials on September 21, and 60,000 signed up to participate in the study.
also read
Solberg expects a corona vaccine this winter
– We must respect the privacy of the participant. We are also investigating the participant’s illness, and it is important that we have all the facts on the table before providing further information, the company writes in the press release, adding:
– Side effects, illnesses, accidents etc., even serious, are expected in clinical trials, especially large studies.
Dr. William Schaffner, a professor at Vanderbilt Medical University, told Reuters it could take weeks to get the information needed to start testing again.
– It must be a serious side effect. For example, if it were prostate cancer, uncontrolled diabetes, or a heart attack, they wouldn’t stop. It is probably a neurological event, he says.
Several countries have entered into agreements to purchase the vaccine. On October 8, the EU agreed to buy up to 400 million doses from all EU countries and Norway, if the vaccine is safe and effective against Covid-19. The United States ordered 100 million through Operation Warp Speed. This is also one of the vaccines the UK is targeting.
In early September, all tests on the AstraZeneca vaccine, which is being developed in collaboration with the University of Oxford, were suspended due to illness in a participant from the UK. According to Reuters, they have started testing again in the UK, South Africa, Brazil and India, while waiting for the green light to start testing again in the US.
So far, five vaccines have been approved for use in at least one country, but so far none have been approved for use in EU countries, the GBV vaccine overview shows. A total of ten vaccines are in phase three.
On October 1, the EU Medicines Agency started analyzing the research results to assess whether the AstraZeneca vaccine can be approved in the EU / Norway.
